Posted by Michael Wonder on 24 Oct 2017
Hundreds of people with diabetes are set to benefit from the funding of a new treatment that will help prevent blindness
24 October 2017 - From 1 November 2017 dexamethasone implants (brand name Ozurdex) will be funded for eligible people with diabetic macular oedema (DMO), a serious complication of type 1 and type 2 diabetes that can cause blindness if untreated.
The dexamethasone implants will be funded for people who have diabetic macular oedema, have had cataract surgery and meet the other special authority criteria.
PHARMAC Director of Operations, Sarah Fitt, says the new treatment is a significant advance in the way diabetic macular oedema is treated for those who meet the criteria.
